Provectus Biopharmaceuticals, Stock Price - PVCT

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
$49.05
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Provectus Biopharmaceuticals, Inc. (QB) PVCT OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0005 0.76% 0.066 0.066 0.062 0.062 0.0655 16:30:08
Bid Price Ask Price Spread Spread % News
0.062 0.10 0.038 38.0% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
16 49,695 $ 0.063740 $ 3,168 196,353 0.0111 - 0.075
Last Trade Time Type Quantity Stock Price Currency
15:59:46 1,000 $ 0.066 USD

Provectus Biopharmaceuticals, Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 25.65M 388.58M $ -8.15M - - 358.04M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.08M $ - 0.00% - -

more financials information »

Provectus Biopharmaceuticals, News

Loading Messages....

Latest PVCT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PVCT Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.0670.0680.0620.063889k-0.001-1.49%
1 Month0.06810.06950.0480.0645136k-0.0021-3.08%
3 Months0.06850.0740.0480.0654192k-0.0025-3.65%
6 Months0.05010.07490.01110.0608232k0.015931.74%
1 Year0.07390.0750.01110.0610248k-0.0079-10.69%
3 Years0.03210.0920.0110.0374962k0.0339105.61%
5 Years0.0350.0920.0110.0374969k0.03188.57%

Provectus Biopharmaceuticals, Description

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for psoriasis. In addition, Provectus has begun a Phase 3 trial as a therapy for metastatic melanoma. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.